Healthcare
Gain Therapeutics, Inc.(GANX)
Live Price
Offline$1.88
+5.62% today
1Y Change
-3.59%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $80.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +31.5%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Gain Therapeutics, Inc. (GANX) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $1.88 and down 3.6% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +31.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +31.5%, free cash flow +2.3% with operating margin 0.0% and ROIC -95.0%. Stock Foundry combines GANX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +31.5%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.4% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +2.2% | -7.3% | -5.1% |
2026 Mar 26, 2026 | +21.4% | -3.2% | -2.1% | +4.2% |
2025 Nov 12, 2025 | +0.0% | +1.4% | -6.8% | +39.3% |
Benchmark Edge
GANX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GANX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GANX Max Drawdown
-61.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GANX and SPY.
Company Overview
Gain Therapeutics, Inc.
NASDAQ Global Market
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
- Leadership
- Gene Mack
- IPO Date
- Mar 19, 2021
- Employees
- 23
- Street Address
- 4800 Montgomery Lane
- Mailing
- Bethesda, MD, 20814
- Region
- Bethesda, MD, US
- Reporting Currency
- USD
- Investor Line
- 301 500 1556
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.4
Growth
- Revenue
- 0.0%
- EPS
- +31.5%
- Free Cash Flow
- +2.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -237.5%
- ROIC
- -95.0%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 6.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.